BioMedReports.com Extreme Trades: ACAD, ANPI, BSTC, RPRX, SNTS
Bullish Bankers (June 16th, 2009) Writes:
Below are four companies with market caps under $200 million (all financial data current as of 6/9/09 during intraday trading) which have pending FDA decisions and/or clinical trial results that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in Extreme FDA and Clinical Trial Calendar Trades, which are highlighted in periodic articles at BioMedReports.com. Another approach is to simply buy such companies well ahead of their expected catalyst dates for a possible stock price increase as the date approaches and trading activity increases.
1.) Angiotech Pharma [ANPI: 1.97, 0.00 (0.00%)] – currently trading at $2.14, market cap = $182 million
ANPI has an FDA-approved dialysis catheter (HemoStream) that is sold through its direct sales
...5-FU anti-infective ;, 5-FU anti-infective technology;, anemia, ANPI;, anti-infective technology;, artery disease;, bicarbonate product;, BioSpecifics Technologies;, bullish bankers, California, Canada, cancer, contracture;, Cook Medical Inc.;, dialysis, endometriosis, Europe, Fda, Financial, Germany, HealthCare Products Inc.;, HemoStream;, implantable devices;, Japan, Korea, Market Commentary, Mike Havrilla, New Drug;, paclitaxel technology;, Pfizer, Proellex;, proton pump inhibitor products;, San Diego, Santarus Inc;, Schering Plough, Securities And Exchange Commission, Society of Interventional Radiology;, sodium bicarbonate;, stent product;, treatment of various types of cancer;, United States, USD, uterine fibroids;, Xiaflex;, Zegerid;, Zilver PTX stent;, Zilver PTX;, ZPE-201;, ZPU-301;, ZPU-302;


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)
